Pfizer finally begins Phase III for GlycoMimetics sickle cell drug

GlycoMimetics will receive the final $20m of a $35m milestone payment from Pfizer now that the big pharma company has initiated a long-delayed Phase III clinical trial for rivipansel (GMI-1070) in the treatment of patients hospitalized for painful vaso-occlusive crises associated with sickle cell disease.